Compare Summit Therapeutics Inc (SMMT) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Tyson Foods, Inc. — how do they compare? Summit Therapeutics Inc trades at $17.52 (market cap $13.79B), while Tyson Foods, Inc. trades at $52.15 (market cap $18.39B). The key difference: Tyson Foods, Inc. is the larger of the two by market cap, and Tyson Foods, Inc. pays a 3.9% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SMMT | TSN | |
|---|---|---|
Market Cap | $13.79B | $18.39B |
Sector | Health | Consumer Staples |
52-Week High | $26.38 | $68.75 |
52-Week Low | $12.43 | $50.72 |
Enterprise Value | $13.11B | $25.66B |
Dividend Yield | — | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.
The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.
Tyson Foods (TSN) trades at $52.28, up 1.67% today, with mixed technical signals showing bearish moving averages but oversold RSI levels. Fundamentally, the company reported Q2 2026 EPS of $0.99 beating expectations, though revenue growth guidance was recently cut to 1.5%-2.0% for fiscal 2026 due to beef segment pressures. Valuation metrics show a P/E of 32.27 and P/S of 0.33, with analyst consensus leaning bullish despite recent negative news flow.
The stock presents a contrarian opportunity with oversold technical conditions and positive analyst targets averaging $69, but faces significant headwinds from operational challenges in the beef business and ongoing legal investigations. Investors must weigh the attractive valuation multiples against execution risks and margin pressures in the current operating environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
